- EIB provides a €100 million loan to Orion Pharma to develop oncology, pain and other treatments.
- Funds will cover personnel, clinical trials, patenting and specialized laboratory equipment across Orion's European R&D centres.
- Financing aims to bolster EU supply security for critical medicines; Orion produces active pharmaceutical ingredients and joins the EU Critical Medicines Alliance.
- This is Orion's fifth project supported by the EIB Group.
Loan details
The European Investment Bank is lending €100 million to Orion Pharma to advance treatments in oncology, pain and other conditions with limited options; funding will support personnel, clinical trials, patenting and specialised laboratory equipment across Orion’s European R&D centres.
R&D and supply impact
By reinforcing Orion’s long-term R&D capacity, the financing aims to boost Europe’s advanced biopharmaceutical development and contribute to supply security for essential medicines; Orion produces active pharmaceutical ingredients and participates in the EU Critical Medicines Alliance to reduce supply-chain vulnerabilities.
Project context
This is Orion’s fifth project supported by the EIB Group, which serves as the EU’s financing arm and mobilises private investment for high‑risk innovative projects across strategic policy priorities.
